PDF(Sci-hub)
Abstract：
UNASSIGNED: Hybrid closed-loop (HCL) devices can achieve tight glycemic control but are rarely used in pregnancy, which remains an off-label indication. We present a case of a pregnant patient with type 1 diabetes mellitus (T1DM) who used the Medtronic MiniMed 670G HCL system.
UNASSIGNED: MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy.
UNASSIGNED: An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (<3.7 mmol/mol, <63 mg/dL) remained below the optimal 4% level during the gestation. Finally, a healthy male baby was born at week 37. No safety events were recorded.
UNASSIGNED: This case represents the successful off-label use of HCL during pregnancy in a patient with T1DM.
UNASSIGNED: MiniMed 670G includes an advanced automode option (HCL therapy), which our patient used from the first trimester to the end of the pregnancy.
UNASSIGNED: An unplanned pregnancy was detected in the T1DM patient, with a glycated hemoglobin level of 8.7 mmol/L (7.1%). The patient started sensor-augmented pump therapy at week 13. Subsequently, she entered automode (HCL) at week 16. The time in range (3.7-7.8 mmol/mol, 63-140 mg/dL) increased from 46.8% to 51.3% after HCL initiation. The glycated hemoglobin level remained close to 48 mmol/mol (6.5%) until the end of the pregnancy. Furthermore, the time under range (<3.7 mmol/mol, <63 mg/dL) remained below the optimal 4% level during the gestation. Finally, a healthy male baby was born at week 37. No safety events were recorded.
UNASSIGNED: This case represents the successful off-label use of HCL during pregnancy in a patient with T1DM.
摘要：
■混合闭环（HCL）装置可实现严格的血糖控制，但在怀孕期间很少使用，这仍然是一个标签外的指示。我们介绍了一例使用MedtronicMiniMed670GHCL系统的1型糖尿病（T1DM）孕妇。
■MiniMed670G包括高级自动编码选项（HCL治疗），我们的病人从怀孕的前三个月一直用到怀孕结束。
■在T1DM患者中检测到非计划妊娠，糖化血红蛋白水平为8.7mmol/L（7.1％）。患者在第13周开始传感器增强泵治疗。随后，她在第16周进入自动编码（HCL）。时间范围（3.7-7.8mmol/mol，63-140mg/dL）在HCL开始后从46.8%增加到51.3%。糖化血红蛋白水平保持接近48mmol/mol(6.5%)直到妊娠结束。此外，在范围内的时间(<3.7mmol/mol，<63mg/dL）在妊娠期间保持在最佳4％水平以下。最后,一个健康的男婴在37周出生。没有安全事件记录。
■该病例代表1例T1DM患者在妊娠期间成功使用HCL。
■MiniMed670G包括高级自动编码选项（HCL治疗），我们的病人从怀孕的前三个月一直用到怀孕结束。
■在T1DM患者中检测到非计划妊娠，糖化血红蛋白水平为8.7mmol/L（7.1％）。患者在第13周开始传感器增强泵治疗。随后，她在第16周进入自动编码（HCL）。时间范围（3.7-7.8mmol/mol，63-140mg/dL）在HCL开始后从46.8%增加到51.3%。糖化血红蛋白水平保持接近48mmol/mol(6.5%)直到妊娠结束。此外，在范围内的时间(<3.7mmol/mol，<63mg/dL）在妊娠期间保持在最佳4％水平以下。最后,一个健康的男婴在37周出生。没有安全事件记录。
■该病例代表1例T1DM患者在妊娠期间成功使用HCL。
